Published in Cancer on August 01, 2006
The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. Am J Pathol (2007) 1.46
Podoplanin associates with CD44 to promote directional cell migration. Mol Biol Cell (2010) 1.20
Lymphangiogenesis induced by VEGF-C and VEGF-D promotes metastasis and a poor outcome in breast carcinoma: a retrospective study of 61 cases. Clin Exp Metastasis (2008) 1.17
Tumor lymphangiogenesis and metastasis to lymph nodes induced by cancer cell expression of podoplanin. Am J Pathol (2010) 1.13
Impact of podoplanin expression in oral squamous cell carcinoma: clinical and histopathologic correlations. Virchows Arch (2010) 1.02
Immunohistochemical examination on the distribution of cells expressed lymphatic endothelial marker podoplanin and LYVE-1 in the mouse tongue tissue. Acta Histochem Cytochem (2010) 1.01
Podoplanin expression in the development and progression of laryngeal squamous cell carcinomas. Mol Cancer (2010) 1.00
Podoplanin expressing cancer associated fibroblasts are associated with unfavourable prognosis in adenocarcinoma of the esophagus. Clin Exp Metastasis (2012) 0.99
Podoplanin expression in cancer-associated fibroblasts enhances tumor progression of invasive ductal carcinoma of the pancreas. Mol Cancer (2013) 0.98
DeltaNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oral cancer in patients with leukoplakia. Clin Cancer Res (2009) 0.97
Cancer stem cell markers in head and neck squamous cell carcinoma. Stem Cells Int (2013) 0.97
A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin. Sci Rep (2014) 0.97
Plant lectin can target receptors containing sialic acid, exemplified by podoplanin, to inhibit transformed cell growth and migration. PLoS One (2012) 0.95
Lymphatic Vessel Density and Vascular Endothelial Growth Factor Expression in Squamous Cell Carcinomas of Lip and Oral Cavity: A Clinicopathological Analysis with Immunohistochemistry Using Antibodies to D2-40, VEGF-C and VEGF-D. Yonago Acta Med (2013) 0.94
Expression of podoplanin in the mouse tooth germ and apical bud cells. Acta Histochem Cytochem (2008) 0.94
Combined-modality treatment in advanced oral squamous cell carcinoma: Primary surgery followed by adjuvant concomitant radiochemotherapy. Strahlenther Onkol (2011) 0.93
Prognostic value of podoplanin expression in intratumoral stroma and neoplastic cells of uterine cervical carcinomas. Clinics (Sao Paulo) (2010) 0.92
Antibody and lectin target podoplanin to inhibit oral squamous carcinoma cell migration and viability by distinct mechanisms. Oncotarget (2015) 0.92
How useful is the assessment of lymphatic vascular density in oral carcinoma prognosis? World J Surg Oncol (2007) 0.91
Podoplanin in cancer cells is experimentally able to attenuate prolymphangiogenic and lymphogenous metastatic potentials of lung squamoid cancer cells. Mol Cancer (2010) 0.91
SRC points the way to biomarkers and chemotherapeutic targets. Genes Cancer (2012) 0.88
The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity. Oncotarget (2015) 0.87
Podoplanin in the development and progression of oral cavity cancer: a preliminary study. Oral Implantol (Rome) (2012) 0.87
Immunohistochemical Examination of Novel Rat Monoclonal Antibodies against Mouse and Human Podoplanin. Acta Histochem Cytochem (2012) 0.86
Prognostic significance of lymphangiogenesis in pharyngolaryngeal carcinoma patients. BMC Cancer (2010) 0.85
Podoplanin mediates ECM degradation by squamous carcinoma cells through control of invadopodia stability. Oncogene (2014) 0.85
CARP-1 functional mimetics are a novel class of small molecule inhibitors of malignant pleural mesothelioma cells. PLoS One (2014) 0.84
Increased expression of Rab coupling protein in squamous cell carcinoma of the head and neck and its clinical significance. Oncol Lett (2012) 0.82
Concordant podoplanin expression in cancer-associated fibroblasts and tumor cells is an adverse prognostic factor in esophageal squamous cell carcinoma. Int J Clin Exp Pathol (2014) 0.81
Characterization of monoclonal antibody LpMab-3 recognizing sialylated glycopeptide of podoplanin. Monoclon Antib Immunodiagn Immunother (2015) 0.81
Podoplanin - a small glycoprotein with many faces. Am J Cancer Res (2016) 0.81
Oral premalignancy: the roles of early detection and chemoprevention. Otolaryngol Clin North Am (2013) 0.79
Podoplanin is a novel myoepithelial cell marker in pleomorphic adenoma and other salivary gland tumors with myoepithelial differentiation. Virchows Arch (2012) 0.79
Suppression of Aggrus/podoplanin-induced platelet aggregation and pulmonary metastasis by a single-chain antibody variable region fragment. Cancer Med (2014) 0.79
Phosphorylated mTOR expression correlates with podoplanin expression and high tumor grade in esophageal squamous cell carcinoma. Int J Clin Exp Pathol (2015) 0.79
The multifaceted role of podoplanin expression in hepatocellular carcinoma. Eur J Histochem (2017) 0.78
Expression of podoplanin and vimentin is correlated with prognosis in esophageal squamous cell carcinoma. Mol Med Rep (2015) 0.78
Expression of podoplanin in salivary gland adenoid cystic carcinoma and its association with distant metastasis and clinical outcomes. Mol Med Rep (2012) 0.78
Expression of Podoplanin in Different Grades of Oral Squamous Cell Carcinoma. Ann Med Health Sci Res (2015) 0.77
Podoplanin is a component of extracellular vesicles that reprograms cell-derived exosomal proteins and modulates lymphatic vessel formation. Oncotarget (2016) 0.77
Expression of podoplanin in the invasion front of oral squamous cell carcinoma is not prognostic for survival. Virchows Arch (2015) 0.77
Clinicopathology significance of podoplanin immunoreactivity in esophageal squamous cell carcinoma. Int J Clin Exp Pathol (2014) 0.76
Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin, using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN. Cancer Med (2017) 0.76
Are podoplanin and ezrin involved in the invasion process of the ameloblastomas? Eur J Histochem (2015) 0.76
Biomarkers predicting malignant progression of laryngeal epithelial precursor lesions: a systematic review. Eur Arch Otorhinolaryngol (2011) 0.76
Histopathological and immunohistochemical study in keratocystic odontogenic tumors: Predictive factors of recurrence. Oncol Lett (2017) 0.75
Immunohistochemical analysis of oral dysplasia: diagnostic assessment by fascin and podoplanin expression. Acta Histochem Cytochem (2011) 0.75
Relationship of Podoplanin and Glutathione S-transferases T1 Expression with Laryngeal Cancer. Int J Mol Cell Med (2012) 0.75
Expression of HNF-1β in cervical carcinomas: an immunohistochemical study of 155 cases. Diagn Pathol (2015) 0.75
High expression of podoplanin in squamous cell carcinoma of the tongue occurs predominantly in patients ≤40 years but does not correlate with tumour spread. J Pathol Clin Res (2015) 0.75
Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity. Cancer Med (2017) 0.75
Characterization, Localization and Patterning of Lymphatics and Blood Vessels in Oral Squamous Cell Carcinoma: A Comparative Study Using D2-40 and CD-34 IHC Marker. J Clin Diagn Res (2014) 0.75
HuR and podoplanin expression is associated with a high risk of malignant transformation in patients with oral preneoplastic lesions. Oncol Lett (2016) 0.75
The expression of podoplanin protein is a diagnostic marker to distinguish the early Infiltration of esophageal squamous cell carcinoma. Oncotarget (2017) 0.75
ALDH1 and podoplanin expression patterns predict the risk of malignant transformation in oral leukoplakia. Oncol Lett (2016) 0.75
Role of podoplanin expression in deciding the invasive potential of ameloblastoma - A retrospective IHC study. J Oral Biol Craniofac Res (2016) 0.75
Low-risk population among patients with tumor-node-metastasis stage III/IV oral squamous cell carcinoma. Oncol Lett (2017) 0.75
Podoplanin, ezrin, and Rho-A proteins may have joint participation in tumor invasion of lip cancer. Clin Oral Investig (2016) 0.75
Expression of podoplanin and prognosis in oropharyngeal cancer. Eur Arch Otorhinolaryngol (2014) 0.75
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57
Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys (2002) 6.82
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol (2012) 4.77
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res (2007) 4.45
Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst (2009) 4.36
Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol (2009) 3.58
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature (2010) 3.37
Retracted The influence of resection and aneuploidy on mortality in oral leukoplakia. N Engl J Med (2004) 3.22
Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol (2008) 3.16
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol (2012) 3.08
Loss of heterozygosity (LOH) profiles--validated risk predictors for progression to oral cancer. Cancer Prev Res (Phila) (2012) 3.03
Nomogram to predict the benefit of radiation for older patients with breast cancer treated with conservative surgery. J Clin Oncol (2012) 2.85
Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center. Clin Trials (2009) 2.79
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst (2012) 2.79
Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. J Clin Oncol (2009) 2.75
Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine. Clin Trials (2008) 2.71
Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst (2006) 2.61
Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res (2010) 2.56
Redesigning radiotherapy quality assurance: opportunities to develop an efficient, evidence-based system to support clinical trials--report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance. Int J Radiat Oncol Biol Phys (2012) 2.55
Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol (2002) 2.52
Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res (2002) 2.50
Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol (2009) 2.48
Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. J Clin Oncol (2012) 2.48
Effects of propofol and ketamine as combined anesthesia for electroconvulsive therapy in patients with depressive disorder. J ECT (2012) 2.43
Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol (2007) 2.40
Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol (2012) 2.31
t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway. Nat Genet (2003) 2.30
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res (2012) 2.27
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24
Aquaporin 1 is overexpressed in lung cancer and stimulates NIH-3T3 cell proliferation and anchorage-independent growth. Am J Pathol (2006) 2.19
Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. J Clin Oncol (2009) 2.15
Transcriptomic dissection of tongue squamous cell carcinoma. BMC Genomics (2008) 2.09
Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila) (2009) 1.99
Understanding the biological basis of autofluorescence imaging for oral cancer detection: high-resolution fluorescence microscopy in viable tissue. Clin Cancer Res (2008) 1.92
A novel polymorphism in human cytosine DNA-methyltransferase-3B promoter is associated with an increased risk of lung cancer. Cancer Res (2002) 1.87
High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. Cancer Res (2006) 1.84
PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One (2011) 1.80
Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res (Phila) (2010) 1.80
Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol (2011) 1.79
Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene. J Natl Cancer Inst (2007) 1.79
Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin Cancer Res (2004) 1.76
Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial. J Natl Cancer Inst (2003) 1.75
Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol (2009) 1.74
Mortality risk from squamous cell skin cancer. J Clin Oncol (2005) 1.74
Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system. Cancer Prev Res (Phila) (2009) 1.71
A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. Cancer Prev Res (Phila) (2011) 1.70
Objective detection and delineation of oral neoplasia using autofluorescence imaging. Cancer Prev Res (Phila) (2009) 1.66
Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol (2009) 1.66
Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis (2005) 1.61
Noninvasive evaluation of oral lesions using depth-sensitive optical spectroscopy. Cancer (2009) 1.61
Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. J Clin Oncol (2007) 1.61
Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res (2009) 1.60
Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. J Natl Cancer Inst (2010) 1.59
High-dose fenretinide in oral leukoplakia. Cancer Prev Res (Phila) (2009) 1.59
Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain Behav Immun (2010) 1.58
Proliferative changes in the bronchial epithelium of former smokers treated with retinoids. J Natl Cancer Inst (2007) 1.58
Human telomerase reverse transcriptase (hTERT) and Ki-67 are better predictors of survival than established clinical indicators in patients undergoing curative hepatic resection for colorectal metastases. Ann Surg Oncol (2004) 1.58
Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev Res (Phila) (2009) 1.57
Decision analysis for prophylactic cranial irradiation for patients with small-cell lung cancer. J Clin Oncol (2006) 1.57
Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes. J Clin Oncol (2005) 1.54
miR-200 Inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1. Mol Cancer Res (2010) 1.54
Improved tissue-engineered bone regeneration by endothelial cell mediated vascularization. Biomaterials (2008) 1.53
Outcomes in patients with adenoid cystic carcinoma of the lacrimal gland. Ophthal Plast Reconstr Surg (2004) 1.53
Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer. Clin Cancer Res (2008) 1.50
Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol (2002) 1.50
Many patients 80 years and older with advanced non-small cell lung cancer (NSCLC) can tolerate chemotherapy. J Thorac Oncol (2007) 1.48
A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression. Br J Haematol (2003) 1.47
Involvement of aquaporins in colorectal carcinogenesis. Oncogene (2003) 1.45
Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer (2006) 1.45
Global expression-based classification of lymph node metastasis and extracapsular spread of oral tongue squamous cell carcinoma. Neoplasia (2006) 1.44
Pulmonologist involvement, stage-specific treatment, and survival in adults with non-small cell lung cancer and chronic obstructive pulmonary disease. Ann Am Thorac Soc (2015) 1.40
Anterior versus posterior routes of reconstruction after esophagectomy: a comparative anatomic study. Ann Thorac Surg (2009) 1.40
Identification and validation of metastasis-associated proteins in head and neck cancer cell lines by two-dimensional electrophoresis and mass spectrometry. Clin Exp Metastasis (2002) 1.39
Expression signatures of metastatic capacity in a genetic mouse model of lung adenocarcinoma. PLoS One (2009) 1.39
Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol (United States). Cancer Causes Control (2003) 1.39
miRNA expression profiles in head and neck squamous cell carcinoma and adjacent normal tissue. Head Neck (2009) 1.38
Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer (2007) 1.38
Smoking molecular damage in bronchial epithelium. Oncogene (2002) 1.38
A predictive probability design for phase II cancer clinical trials. Clin Trials (2008) 1.37